​UK–Switzerland Leadership Forum

​Building the Future of AI-Driven Scientific Discovery

​Switzerland and the UK are home to two of the world's leading life sciences and AI ecosystems, bringing together world-class research institutions, pioneering technology companies, global pharmaceutical leaders, and deep scientific and investment expertise.

​AI is fundamentally reshaping the way we understand the complexities of biology. As AI evolves into a powerful engine for scientific discovery, it is creating new possibilities for how novel therapeutics are discovered and developed. Realizing this potential will require connecting world-class science, trusted data, advanced technology, investment and industry through deeper collaboration.

​Hosted by the Embassy of Switzerland in London and Owkin, the UK–Switzerland Leadership Forum will convene 80-100 senior leaders from across biopharma, investment, technology, healthcare, academia and government to explore how cross-sector collaboration can advance AI-driven scientific discovery, unlock strategic partnerships and accelerate the transformation of drug R&D.

​Agenda

​5:30 PM – Registration & Networking

​6:00 PM – Welcoming Remarks

• ​Dr. Dominique Paravicini, Ambassador of Switzerland to the United Kingdom

​6:10–6:40 PM – Investing in AI-Driven Drug Discovery

​Speakers:

• ​Pascal Weinberger, Co-CEO, Owkin

• ​Dr. Marc Moesser, Partner, Redalpine

• ​Vishal Gulati, Founder and Managing Partner, Recode Ventures

​Moderator: Prashant Rao, Global Managing Editor, Semafor

​6:40–7:10 PM – AI, Scientific Discovery & the Future of Drug R&D

​Speakers:

• ​Laura Haden-Smith, Director of Business Development, GSK

• ​Hana Aliee, Group Leader in AI, Cancer Research UK / University of Cambridge

• ​Lucie Friedlander, VP Commercial, Owkin

​Moderator: Prashant Rao, Global Managing Editor, Semafor

​7:10 PM – Networking Reception

​9:00 PM – Forum Concludes

​Attendance is by approval only. Registration is not final until confirmed.